Meet Our Executive Team at Op-T LLC.

Op-T’s executive team and the members of its Board bring a wealth of biomedical product development experience, industry connections, and medical insights to support future growth. As a small company, Op-T relies heavily on this experienced core for guidance and feedback and their networks of industry contacts. Among the key contributors to furthering the commercialization of Op-T’s therapeutics are:

Charlie Henry, Op-T Co-Founder, CEO, and President

Charlie Henry brings 35 years of biomedical company development and management experience to his leadership of Op-T. As a CEO, Mr. Henry has worked within the diagnostic, device, and pharmaceutical sectors.

He has raised tens of millions through equity sales, negotiated complex licensing and distribution agreements with international and domestic partners, and led successful corporate sales to public and private acquirers.

David H. Wagner, Jr., PhD, Op-T Co-Founder, CSO

In addition to being CSO at Op-T, Dr. Wagner is an Associate Professor of Medicine at the University of Colorado Anschutz Medical Campus. He has more than 25 years of experience in medical research as an immunologist focused on autoimmune diseases, including type 1 diabetes and Multiple Sclerosis.

He has generated over 10 million dollars in grant funding for medical research. He coordinates all of Op-T’s pre-clinical testing, provides oversight on formulations and routes of administration, is responsible for analyzing data, and contributes to developing new intellectual property. 

Henry H. Haight, IV, Op-T Director

Mr. Haight has 55 years of corporate management and venture capital investment expertise. His corporate management work spans furniture making, telecommunications, biomedical, and security software operations.

As a venture capital investor and fund manager, Mr. Haight was the Managing Director and Sole Founder or Co-Founder of South East Asia Venture Investment Company, Advent International Corporation, Venture Manufacturing Singapore, and Argo Global Capital. In composite, these funds had over $1 billion under management, and most were invested outside the U.S.

Mr. Haight has served on scores of corporate boards and guided his companies through hundreds of corporate transactions at the private and publicly traded levels.

Robert A. Vigersky, MD, Op-T Director

Dr. Vigersky’s unique background in the military, academic, and corporate management of diabetes brings Op-T a high level of expertise in the latest trends in endocrinology, patient care, grant fulfillment, and strategic decision-making.

Dr. Vigersky is currently a Senior Medical Director at Medtronic’s Diabetes Division, Director Emeritus of the Diabetes Institute at the Walter Reed National Military Medical Center, and Colonel (retired) from the U.S. Army Medical Corps. Furthermore, Dr. Vigersky was a Past President of the Endocrine Society and a Professor of Medicine at the Uniformed Services University of the Health Sciences.

Get in Touch

Reach out to us today for more information about our services. We look forward to hearing from you.